Patient perspectives on antipsychotic treatments and their association with clinical outcomes

por Liu-Seifert, Hong, Osuntokun, Olawale O, Godfrey, Jenna L, Feldman, Peter D
Publicado 2010

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, explorator...

por Ascher-Svanum, Haya, Montgomery, William S, McDonnell, David P, Coleman, Kristina A, Feldman, Peter D
Publicado 2012

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

por Ascher-Svanum, Haya, Brnabic, Alan JM, Lawson, Anthony H, Kinon, Bruce J, Stauffer, Virginia L, Feldman, Peter D, Kelin, Katarina
Publicado 2012

T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSY...

por Bugarski-Kirola, Dragana, Nunez, Rene, Odetalla, Ramzey, Bari, Mohammed A, Bitter, Istvan, Feldman, Peter D, (Cathy) Liu, I-Yuan, Stankovic, Srdjan
Publicado 2020